Health Care Businesses

Lilly wins further delay in sales of Strattera copies

August 26, 2010
Bloomberg News
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would translate into an average $1.22 million in sales.
More

Diabetes research pioneer Kirtley dies at 96

August 25, 2010
Associated Press
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a groundbreaking Eli Lilly researcher.
More

Lilly woes take notch out of debt rating

August 25, 2010
J.K. Wall
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s to lower its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based drugmaker will eventually break its string of bad luck on developing new products.
More

Pearl IRB first firm in state to pre-screen clinical drug trialsRestricted Content

August 21, 2010
Chris O'Malley
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
More

Lilly gains panel's backing to expand Cymbalta use

August 19, 2010
Bloomberg News
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee.
More

Lilly wins temporary ban on sales of Strattera copies

August 19, 2010
Bloomberg News
The invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug, which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
More

Cancer drug developer Endocyte files for IPO

August 18, 2010
Scott Olson
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet to be determined.
More

Lilly Alzheimer's drug prospect only the latest to fail

August 18, 2010
Bloomberg News
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the disease since 1906, have failed in mid- to late-stage testing since 2003.
More

Lilly's Cymbalta helps chronic pain in U.S. review

August 17, 2010
Bloomberg News
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's annual sales.
More

Lilly halts development of Alzheimer's drug

August 17, 2010
 IBJ Staff and Associated Press
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through 2014.
More

Medco to acquire United BioSource for $710M

August 16, 2010
 IBJ Staff and Bloomberg News
Medco operates an automated pharmacy and distribution center in Whitestown in Boone County, and it plans to employ more than 1,400 people there by 2012.
More

Bedsore preventer turns to detectionRestricted Content

August 14, 2010
Chris O'Malley
Changes in reimbursement could fuel market for WoundVision's product.
More

Arcadia sees smaller loss, extends WellPoint pact

August 9, 2010
 IBJ Staff
Indianapolis-based health care firm reaches agreement to offer its DailyMed product to more WellPoint Inc. health plan members.
More

Lilly among bidders for Denmark company, source says

July 30, 2010
Bloomberg News
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said. Ascendis may choose a final bidder by early September.
More

Hill-Rom raises profit forecast after quarterly earnings jump

July 29, 2010
J.K. Wall
The Batesville-based maker of hospital beds and furniture announced Wednesday night that it earned $30.6 million in its third quarter, up from $20.2 million in the same quarter of 2009.
More

Lilly loses appeal over patent for cancer drug Gemzar

July 28, 2010
 IBJ Staff and Bloomberg News
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013. Gemzar generated $1.36 billion in global sales in 2009.
More

Lilly completes $180 million acquisition of Alnara

July 21, 2010
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company developing an enzyme-replacement therapy for disorders of the pancreas.
More

Lilly's Alzheimer's gamble takes aim at $10 billion in patent losses

July 13, 2010
Bloomberg News
Both of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more than $5 billion a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
More

Lilly to cut 170 manufacturing jobs by year's end

July 12, 2010
J.K. Wall
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling drugs.
More

Home medical supply firm grows as industry boom approaches

July 10, 2010
Joe Jasinski

David Hartley pulled $85,000 from his savings six years ago to buy Home Health Depot Inc. Nearly six years later, Hartley has reinvented the Indianapolis-based home medical equipment supplier, growing from a single office in Greenwood to 12 locations in Indiana and Illinois—and increasing annual revenue from $300,000 to more than $6.7 million.

More

Men on Viagra, Cialis show triple rate of sex diseases in study

July 6, 2010
 IBJ Staff and Bloomberg News
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly's Cialis, may be more likely to engage in unsafe sex than nonusers.
More

Lilly acquires biotech company with pancreatic drug

July 2, 2010
J.K. Wall
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years, recently submitted its drug to the FDA for market approval.
More

Lilly's Effient steps forward, then back

June 30, 2010
J.K. Wall
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor, Plavix, a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
More

Lilly layoffs pare communications department

June 21, 2010
J.K. Wall
The giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications staff. Most of that staff is based in Indianapolis.
More

Lilly, Amylin stock rises on drug postponement

June 18, 2010
 IBJ Staff and Bloomberg News
Roche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals Inc. and drug partner Eli Lilly and Co.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. PJ - Mall operators like Simon, and most developers/ land owners, establish individual legal entities for each property to avoid having a problem location sink the ship, or simply structure the note to exclude anything but the property acting as collateral. Usually both. The big banks that lend are big boys that know the risks and aren't mad at Simon for forking over the deed and walking away.

  2. Do any of the East side residence think that Macy, JC Penny's and the other national tenants would have letft the mall if they were making money?? I have read several post about how Simon neglected the property but it sounds like the Eastsiders stopped shopping at the mall even when it was full with all of the national retailers that you want to come back to the mall. I used to work at the Dick's at Washington Square and I know for a fact it's the worst performing Dick's in the Indianapolis market. You better start shopping there before it closes also.

  3. How can any company that has the cash and other assets be allowed to simply foreclose and not pay the debt? Simon, pay the debt and sell the property yourself. Don't just stiff the bank with the loan and require them to find a buyer.

  4. If you only knew....

  5. The proposal is structured in such a way that a private company (who has competitors in the marketplace) has struck a deal to get "financing" through utility ratepayers via IPL. Competitors to BlueIndy are at disadvantage now. The story isn't "how green can we be" but how creative "financing" through captive ratepayers benefits a company whose proposal should sink or float in the competitive marketplace without customer funding. If it was a great idea there would be financing available. IBJ needs to be doing a story on the utility ratemaking piece of this (which is pretty complicated) but instead it suggests that folks are whining about paying for being green.

ADVERTISEMENT